NASDAQ:MRVI - Maravai LifeSciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $51.50
  • Forecasted Upside: 75.65 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$29.32
▼ -0.08 (-0.27%)

This chart shows the closing price for MRVI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Maravai LifeSciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MRVI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MRVI

Analyst Price Target is $51.50
▲ +75.65% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Maravai LifeSciences in the last 3 months. The average price target is $51.50, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 75.65% upside from the last price of $29.32.

This chart shows the closing price for MRVI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Maravai LifeSciences.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/11/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/6/2022Robert W. BairdLower Price Target$48.00 ➝ $40.00High
2/25/2022Morgan StanleyLower Price TargetOverweight$59.00 ➝ $54.00High
2/24/2022Robert W. BairdLower Price Target$60.00 ➝ $48.00Medium
8/12/2021Morgan StanleyBoost Price TargetOverweight$54.00 ➝ $62.00High
8/11/2021Credit Suisse GroupBoost Price TargetOutperform$44.00 ➝ $54.00High
8/11/2021KeyCorpBoost Price TargetOverweight$46.00 ➝ $58.00High
8/11/2021Robert W. BairdBoost Price TargetOutperform$51.00 ➝ $59.00High
8/5/2021Credit Suisse GroupInitiated CoverageOutperform$44.00Low
5/11/2021Credit Suisse GroupBoost Price TargetOutperform$42.00 ➝ $44.00Low
3/8/2021Credit Suisse GroupBoost Price TargetOutperform$34.00 ➝ $42.00N/A
3/3/2021Morgan StanleyBoost Price TargetOverweight$35.00 ➝ $54.00High
3/3/2021KeyCorpBoost Price TargetOverweight$39.00 ➝ $46.00High
3/1/2021Credit Suisse GroupBoost Price TargetOutperform$31.00 ➝ $34.00Low
2/10/2021KeyCorpBoost Price TargetOverweight$33.00 ➝ $39.00Low
12/16/2020KeyCorpInitiated CoverageOverweight$33.00N/A
12/15/2020Morgan StanleyInitiated CoverageOverweight$35.00Low
12/15/2020Stifel NicolausInitiated CoverageBuy$31.00Medium
12/15/2020William BlairInitiated CoverageOutperformMedium
12/15/2020Credit Suisse GroupInitiated CoverageOutperformMedium
12/15/2020The Goldman Sachs GroupInitiated CoverageBuy$38.00Medium
12/15/2020Bank of AmericaInitiated CoverageBuy$31.00Medium
12/15/2020Jefferies Financial GroupInitiated CoverageBuyMedium
12/15/2020Robert W. BairdInitiated CoverageOutperform$31.00Medium
12/14/2020UBS GroupInitiated CoverageBuy$32.00Low
(Data available from 7/6/2017 forward)

News Sentiment Rating

0.45 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/8/2021
  • 6 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/7/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/6/2022
  • 2 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/8/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/7/2022
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/7/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/6/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/6/2022

Current Sentiment

  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Maravai LifeSciences logo
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $29.32
Low: $28.31
High: $29.55

50 Day Range

MA: $30.36
Low: $26.05
High: $35.69

52 Week Range

Now: $29.32
Low: $23.16
High: $63.55

Volume

751,055 shs

Average Volume

1,867,327 shs

Market Capitalization

$7.48 billion

P/E Ratio

18.44

Dividend Yield

N/A

Beta

0.85

Frequently Asked Questions

What sell-side analysts currently cover shares of Maravai LifeSciences?

The following sell-side analysts have issued reports on Maravai LifeSciences in the last year: Credit Suisse Group AG, KeyCorp, Morgan Stanley, and Robert W. Baird.
View the latest analyst ratings for MRVI.

What is the current price target for Maravai LifeSciences?

0 Wall Street analysts have set twelve-month price targets for Maravai LifeSciences in the last year. Their average twelve-month price target is $51.50, suggesting a possible upside of 75.6%.
View the latest price targets for MRVI.

What is the current consensus analyst rating for Maravai LifeSciences?

Maravai LifeSciences currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MRVI will outperform the market and that investors should add to their positions of Maravai LifeSciences.
View the latest ratings for MRVI.

How do I contact Maravai LifeSciences' investor relations team?

Maravai LifeSciences' physical mailing address is 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA, 92121. The company's listed phone number is 858-546-0004 and its investor relations email address is [email protected] The official website for Maravai LifeSciences is www.maravai.com. Learn More about contacing Maravai LifeSciences investor relations.